Is It Safe to Use Cannabis with Ketamine Therapy?

If you use cannabis (marijuana, THC products, edibles, vapes) and are considering at-home ketamine therapy, the combination is safe in the acute medical sense at typical doses but the effectiveness question is real. Daily THC use measurably blunts ketamine's antidepressant response through the same BDNF and neuroplasticity pathways that the alcohol page covers; occasional weekend use between sessions is less clearly problematic; CBD-only products are generally fine throughout the course. The standard guidance: pause THC during the initial loading phase, abstain on session days, and have an honest conversation at intake about pattern.

Why this question deserves a real answer

Cannabis use is now common across the patient population we treat. With recreational legalization across many states and medical legalization in nearly all, including Florida and New Jersey where Tovani operates, patients arriving for ketamine therapy often have a real and ongoing cannabis use pattern. The conversation isn't "do you ever use marijuana"; it's about pattern, product, and how to fit it around ketamine treatment.

The question deserves an honest answer because the field's clinical reflex has been variable. Some clinics treat cannabis as a hard contraindication; others ignore it. Neither is right. The published evidence and Tovani's clinical experience support a more nuanced position that takes the pharmacology seriously without being unnecessarily restrictive.

The pharmacology question

Cannabis's two principal active components have very different profiles. THC (tetrahydrocannabinol) is the psychoactive cannabinoid responsible for the characteristic intoxication. It binds CB1 receptors throughout the brain, modulates glutamate release, alters dopamine signaling in reward pathways, and produces the dissociation, euphoria, anxiety, and cognitive effects users recognize. CBD (cannabidiol) is the non-psychoactive cannabinoid that has anxiolytic, anti-inflammatory, and possible anti-seizure effects without producing intoxication.

For ketamine specifically, the relevant question is what each does to the neuroplasticity window that ketamine opens. Ketamine's antidepressant effect depends on a several-day post-session period during which BDNF rises and synaptic plasticity is enhanced. Substances that suppress BDNF release, dampen glutamate signaling, or interfere with the downstream plasticity signaling blunt the antidepressant response.

THC does interfere with this window. The CB1 receptor activation modulates glutamate release in mood-relevant brain regions, and chronic THC use produces measurable changes in BDNF signaling and synaptic plasticity that are in the wrong direction for what ketamine is trying to do. The mechanism is different from alcohol's GABA-mediated effect, but the downstream outcome is similar: smaller and shorter-lived ketamine response in heavy users.

CBD does not have this profile. At typical doses (whether for sleep, anxiety, or pain), CBD does not produce meaningful neuroplasticity blunting and does not interfere with the ketamine antidepressant cascade. There is one minor pharmacokinetic note: CBD at high doses inhibits CYP3A4, and ketamine is partly CYP3A4-metabolized, so theoretical PK slowing exists similar to what we covered on the Prozac page. Clinically this rarely matters at at-home ketamine doses.

What we recommend by pattern

The conversation at intake breaks into a few patterns, and the recommendation differs across them.

Daily THC use (multiple times per day, every day): This is the pattern most likely to produce blunted ketamine response. We recommend a meaningful pause through the initial loading phase (10+ ketamine sessions over 4-8 weeks) to give the treatment its best shot. Patients are not always willing or able to do this, and we don't insist; we have the honest conversation about realistic response trajectory and let you make the call.

Daily CBD use (no THC): Generally fine to continue throughout the ketamine course. Some patients use CBD specifically for sleep or anxiety and continuing it during ketamine treatment doesn't change anything we'd do.

Heavy weekend or every-few-days THC use: A middle case. The neuroplasticity-blunting effect is dose-dependent and frequency-dependent. Patients who use heavily on weekends but not during the week often see partial blunting of response without total loss. We discuss the pattern honestly and recommend pausing during the loading phase if you can; if you can't, we proceed with calibrated expectations.

Occasional THC use (a few times per month or less): Probably minimal impact on response. Session-day abstinence still applies (no use 24 hours before or after a ketamine session) but we don't insist on loading-phase abstinence for patients in this category.

Medical THC for chronic pain or other indications: A separate conversation about coordination with your prescribing physician. Some patients have legitimate medical reasons for daily THC that are not modifiable; we work with that and have an honest conversation about realistic ketamine response.

The session-day rule

On a ketamine session day, no cannabis use 24 hours before or after, similar to the alcohol rule. The reasoning is also similar: both ketamine and high-dose cannabis can produce dissociation, and combining them on the same day creates an unpredictable acute experience that is not therapeutically useful. The treatment session is designed to be a controlled, predictable experience; substances on board make it less predictable in ways that don't add anything.

This rule applies to THC products specifically. CBD-only products do not require the session-day hold.

The loading-phase recommendation

The initial 10+ ketamine sessions over 4-8 weeks (the loading phase) is when neuroplasticity matters most and when the cumulative antidepressant response is being established. We strongly encourage pausing THC during this window for patients who can. This is not because cannabis is dangerous; it's because the published evidence and our clinical experience consistently show better response in patients who protect the neuroplasticity window.

After the loading phase, on a maintenance schedule with longer intervals between sessions, occasional cannabis use is generally fine on non-treatment days. Heavy or daily use is still likely to attenuate the maintenance benefit over time.

What we do at intake

When a patient discloses cannabis use, our intake process includes:

The form. Smoking, vaping, edibles, oils, topicals, tinctures. Each has different onset and duration profiles.

The frequency. Multiple times daily, daily, several times weekly, weekend-only, monthly, occasional.

THC vs CBD content. Many patients use THC-dominant products; some use CBD-only; some use balanced products. The distinction matters for our recommendation.

The indication. Recreational, medical (and what condition), or both. Medical use for chronic pain in particular shapes a different conversation than recreational use.

Whether you're willing or able to pause during the loading phase. This is the key question for setting realistic expectations.

For most patients this is a brief honest conversation and we proceed with ketamine onboarding with calibrated guidance. Patients with very heavy use patterns may benefit from a coordinated reduction-then-ketamine approach rather than ketamine on top of heavy daily use.

The patient-honesty issue

A note worth being explicit about. Tovani is not a setting where cannabis use is judged or reported anywhere outside the clinical record. We ask about cannabis use the way we ask about alcohol use: honestly, because the answer affects treatment planning, not as moral inquiry. Patients sometimes minimize cannabis use at intake out of habit (other clinical settings have been judgmental); we want to know your actual pattern so we can give you the most accurate clinical guidance. Underreporting use at intake will simply produce a less-accurate response prediction; it doesn't help anything.

Bottom line

Cannabis with at-home ketamine therapy is a case-by-case question driven by use pattern, product type, and treatment phase. Daily THC use blunts ketamine response and we recommend pausing during the loading phase. Occasional THC use between sessions is less clearly problematic; session-day abstinence (24 hours before and after) still applies. CBD-only products are generally fine throughout the course. The conversation at intake is honest and non-judgmental; the goal is to give your ketamine course the best chance of producing durable response, which is mostly about protecting the neuroplasticity window during the loading phase.